Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe.
carfilzomib
multiple myeloma
proteasome inhibitor
real world
relapsed/refractory
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Oct 2022
28 Oct 2022
Historique:
received:
30
09
2022
revised:
24
10
2022
accepted:
26
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
This prospective, observational study examined the real-world use of carfilzomib across 11 European countries in adults with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy. Carfilzomib and dexamethasone (Kd) use, effectiveness and safety were analyzed. In total, 271 patients received Kd among 701 adults enrolled. The median relative dose intensity of carfilzomib was 82.7% (20/56 mg/m
Identifiants
pubmed: 36358731
pii: cancers14215311
doi: 10.3390/cancers14215311
pmc: PMC9657308
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Hematol. 2019 Jan;98(1):1-18
pubmed: 30470875
Eur J Haematol. 2022 Oct;109(4):373-380
pubmed: 35749094
Blood. 2012 Aug 2;120(5):947-59
pubmed: 22645181
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Blood Adv. 2020 Nov 10;4(21):5449-5459
pubmed: 33166401
Lancet Oncol. 2017 Oct;18(10):1327-1337
pubmed: 28843768
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
J Hematol Oncol. 2018 Apr 4;11(1):49
pubmed: 29615082
Cancers (Basel). 2022 Oct 28;14(21):
pubmed: 36358731
Adv Ther. 2018 Nov;35(11):1763-1774
pubmed: 30357570
Leukemia. 2019 Dec;33(12):2934-2946
pubmed: 31092895
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484
Expert Rev Hematol. 2018 Mar;11(3):219-237
pubmed: 29415570
Blood Cancer J. 2018 Nov 23;8(12):123
pubmed: 30470751
Future Oncol. 2022 Aug;18(24):2661-2674
pubmed: 35815645
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1-7
pubmed: 31767529
Lancet Oncol. 2021 Mar;22(3):e105-e118
pubmed: 33662288
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Leukemia. 2017 Jan;31(1):115-122
pubmed: 27491641
Am J Health Syst Pharm. 2015 Mar 1;72(5):353-60
pubmed: 25694410
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16
pubmed: 31722839
Leukemia. 2020 Jan;34(1):224-233
pubmed: 31427722